RiaSTAP®, Fibrinogen Concentrate (Human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
The effectiveness of RiaSTAP® is based on maximum clot firmness, which measures the structural integrity of a clot, reflecting the underlying effectiveness of the fibrinogen present to form a fibrin clot.
There are no controlled trials demonstrating a direct benefit on treatment of bleeding episodes with RiaSTAP®.
RiaSTAP® is not indicated for dysfibrinogenemia.
For indications, dosing and other information, please refer to the prescribing information.